The US FDA has approved copper histidinate, a copper replacement product indicated for the treatment of Menkes disease in pediatric patients. Copper histidinate is a copper replacement therapy. It delivers copper in a form that bypasses the genetic defect in intestinal absorption, allowing the body to better use the mineral.
Clinical evidence In a clinical study of 83 children (66 treated and 17 untreated), initiating treatment within four weeks of birth reduced the risk of death by nearly 80% and extended median survival to 177.1 months compared with 17.6 months in untreated patients, with no untreated child surviving beyond six years. Dosage and administration Available in the form of a subcutaneous injection Before initiating copper histidinate, obtain baseline serum copper and ceruloplasmin levels, serum electrolytes, kidney and liver function, and complete blood count The…
